Clinical Trial Update: Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing pharmacokinetics of a biosimilar Eptacog Alfa with NovoSeven in patients with congenital Factor VII deficiency has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Factor Vii Deficiency

Drugs mentioned

• Eptacog Alfa (biosimilar) (eptacog alfa)
• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: AryoGen Pharmed Co. | Conditions: Factor VII Deficiency | Phase 3 | Status: COMPLETED